Interferon for anogenital warts in non‐immunocompromised adults
Referencias
Additional references
Arany I, Rady P, Tyring SK. Alterations in cytokine/antioncogene expression in skin lesion caused by 'low‐risk' types of human papillomaviruses. Viral Immunology 1993;6(4):255‐65.
Armstrong DK, Maw RD, Dinsmore WW, Blaakaer J, Correa MA, Falk L, et al. Combined therapy trial with interferon alpha‐2a and ablative therapy in the treatment of anogenital warts. Genitourinary Medicine 1996;72(2):103‐7.
Bergeron C, Ferenczy A, Richart R. Underwear: contamination by human papillomaviruses. American Journal of Obstetrics and Gynecology 1990;162(1):25‐9.
Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. Journal of Clinical Microbiology 1999;37(10):3316‐22.
Cardamakis E, Kotoulas IG, Relakis K, Metalinos K, Michopoulos J, Stathopoulos E, et al. Comparative study of systemic interferon alfa‐2a plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology 1995;45(5):857‐60.
Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant interferon alpha‐2a. A multicenter double‐blind placebo‐controlled clinical trial. Condylomata International Collaborative Study Group. Acta Dermato‐Venereologica 1993;73(3):223‐6.
Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, et al. Immunological events in regressing genital warts. American Journal of Clinical Pathology 1994;102(6):768‐74.
Congilosi SM, Madoff RD. Current therapy for recurrent and extensive anal warts. Diseases of the Colon and Rectum 1995;38(10):1101‐7.
Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18‐ to 59‐year‐olds in the United States, national health and nutrition examination survey, 1999‐2004. Sexually Transmitted Diseases 2008;35(4):357‐60.
Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. The New England Journal of Medicine 1986;315(17):1059‐64.
Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. The New England Journal of Medicine 1985;313(13):784‐8.
Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papilloma virus infections. Obstetrics and Gynecology 1989;74(6):950‐4.
Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Diseases of the Colon and Rectum 1994;37(12):1255‐9.
Friedman‐Kien AE, Eron LJ, Conant M, Growdon W, Badiak H, Bradstreet PW, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988;259(4):533‐8.
George JC, Mark LW. Condylomata acuminata. Problems in General Surgery 2001;18(3):55‐64.
Goon P, Sonnex C. Frequently asked questions about genital warts in the genitourinary medicine clinic: an update and review of recent literature. Sexually Transmitted Infections 2008;84(1):3‐7.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. [updated February 2008].. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org..
Horowitz BJ. Interferon therapy for condylomatous vulvitis. Obstetrics and Gynecology 1989;73(3 Pt 1):446‐8.
Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clinical Infectious Diseases 2003;36(11):1397‐403.
Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus‐related disease in the US: analytic framework and review of the literature. PharmacoEconomics 2005;23(11):1107‐22.
Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts‐related healthcare utilization among privately insured patients in the United States. Sexually Transmitted Diseases 2004;31(12):748‐52.
Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non‐cancerous HPV‐related conditions: HPV‐6/11 disease. Vaccine 2006;24 Suppl 3:S3/35‐41.
Mayeaux EJ, Dunton C. Mordern management of external genital warts. Journal of Lower Genital Tract Disease 2008;12(3):185‐92.
Monsonego J, Cessot G, Ince SE, Galazka AR, Abdul‐Ahad AK. Randomised double‐blind trial of recombinant interferon‐beta for condyloma acuminatum. Genitourinary Medicine 1996;72(2):111‐4.
Obalek S, Jablonska S, Favre M, Walczak L, Orth G. Condylomata acuminata in children: frequent association with human papillomaviruses responsible for cutaneous warts. Journal of the American Academy of Dermatology 1990;23(2 Pt 1):205‐13.
Oriel JD. Natural history of genital warts. The British Journal of Venereal Diseases 1971;47(1):1‐13.
Relakis K, Cardamakis E, Korantzis A, Metalinos K, Mantouvalos H, Papathanasiou Z, et al. Treatment of men with flat (FC) or acuminata (CA) condylomata with interferon alpha‐2a. European Journal of Gynaecological Oncology 1996;17(6):529‐33.
Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourinary Medicine 1990;66(1):16‐9.
Syed TA, Ahmadpour OA. Human leukocyte derived interferon‐alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo‐controlled, double‐blind study. International Journal of STD & AIDS 1998;9(12):769‐72.
Trizna Z, Evans T, Bruce S, Hatch K, Tyring SK. A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata. Sexually Transmitted Diseases 1998;25(7):361‐5.
Wiley DJ, Douglas JM, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment and prevention. Clinical Infectious Diseases 2002;35(Suppl 2):S210‐24.
